Eugia Pharma Receives USFDA Approval for Voriconazole for Injection, 200 mg/Vial Single-Dose Vial
Published: February 02, 2023
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Voriconazole for Injection, 200 mg/Vial Single-Dose Vials.
Indications for this product include:
It is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with:
- Invasive aspergillosis
- Candidemia in non-neutropenics and other deep tissue Candida infections
- Esophageal candidiasis
- Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy